# Regeneron Pharmaceuticals, Inc. (REGN) — Q3-2025 Earnings Results

**Report date:** 2025-10-28 (before market open)  
**Sector:** Health Care / Biotechnology  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/REGN/earnings/Q3-2025

## Post-Earnings Brief

### Headline

Regeneron Pharmaceuticals Beats on EPS, Stock Up 11.82%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.83 | N/A | +57.31% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Confident

Overall, management conveyed confidence in the company's current trajectory. They emphasized their commitment to innovation and growth.

**Key quotes:**

> Management expressed satisfaction with the strong EPS performance.

> They highlighted ongoing research and development efforts.

> No specific guidance was provided for future quarters.

### Guidance Changes

No guidance data is available for future performance.

### What It Means

Regeneron's strong EPS beat indicates robust profitability, which likely boosted investor confidence, leading to an 11.82% increase in stock price. The lack of revenue data makes it difficult to assess overall performance, but the significant EPS surprise suggests effective cost management or strong sales in key products. Investors may view this as a positive sign for the company's future prospects.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/REGN/earnings/Q3-2025_